QuVa Pharma Boosts RFID Capabilities for Injectables

QuVa Pharma, Inc. announced today that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1's open, technology independent, global standards which enable interoperability and compatibility. QuVa' s portfolio of sterile, ready-to-administer syringes will be the first 503B Outsourcing facility to include the pre-tagged RFID GS1 format.

"Insights from our customers and reports like ASHP's that assessed RFID utilization in health systems show a growing desire for pre-tagged open RFID standard products to support increased adoption of medication management systems," said Stuart Hinchen, QuVa Pharma co-founder and CEO. "Understanding hospitals' need for interoperability across their systems that manage inventory, medication dispensing and tracking, and diversion detection provided strong rationale for QuVa to increase investment in our RFID labeling platform."

QuVa will include embedded RFID tags in its products' primary labels for tracking at the unit of use level. QuVa's adoption of GS1 standards will ensure its products are compatible with medication management platforms and other RFID supporting technologies that read GS1 RFID labels. QuVa's pre-tagged, ready-to-administer products are now capable of being read by platforms like IntelliGuard™, AmerisourcBergen's Cubixx®, Healthcare Logistics' Stat Stock™ and Bluesight's Kitcheck providing hospitals greater access to pre-tagged products so they can better leverage these technology platforms and reduce the labor burden—including that of self-tagging.

Continue reading this story here.